Let’s face it: science can be hard.
Our host, Brett Hellman, former soap opera producer and current AbbVie employee, lacks any sort of scientific background and has recurring nightmares of his high school biology class. Now, he is tasked with talking to biopharmaceutical researchers about their work and translating it for the rest of us.
In each episode, Brett will explore some of the toughest and most relevant topics in medical science. This may be, at times, an exercise in frustration for the scientist being interviewed, but listeners will be rewarded with a new understanding not only of science, but about the scientific community at large – with all pretenses stripped down.
The Borax Method of Drug Discovery
One look at the back of a Borax box makes Brett wonder: how can one product do so many different things? Can medicines serve more than one purpose too? How could one medicine treat multiple diseases in totally different parts of the body? And how do researchers figure this stuff out? Brett just doesn’t get it.
In our third episode, Susan E. Lacy, Ph.D., drug discovery scientist, helps Brett see how figuring out what’s behind a disease reveals new possibilities for treatment – and why discovering a new medication for one condition could offer hope for another.
Susan Lacy is a drug discovery scientist and associate director in immuno-oncology, Redwood City, California, U.S.A., focusing on the discovery of new medicines that target cancer-associated fibroblasts to subvert tumor growth. During her 17-year tenure at BASF/Abbott/AbbVie, she has studied biological pathways causing autoimmune disease, chronic kidney disease, and pain. Susan holds a Ph.D. in molecular biology, cancer, and genetics from McMaster University in Hamilton, Ontario, Canada, and completed a Howard Hughes Post-Doctoral Fellowship in human genetics at Harvard Medical School and Boston Children’s Hospital in Boston, Massachusetts, U.S.A.